The Kaplan-Meier analysis showed that there is no significant difference between TP53 mutation status and overall survival in patients with CRC in GEO and TCGA cohorts, which is consistent with previous research [13] (Supplemental Figure S1a,b). This evidence concerns the gene TP53 and colorectal carcinoma.